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ARTICLE
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improved action in vivo
Juliette Fremaux1, Claire Venin1, Laura Mauran1, Robert H. Zimmer1, Gilles Guichard 2 &
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Peptides have gained so much attention in the last decade that they are now part of the main
strategies, with small molecules and biologics, for developing new medicines. Despite sub-
stantial progress, the successful development of peptides as drugs still requires a number of
limitations to be addressed, including short in vivo half-lives and poor membrane perme-
ability. Here, we describe the use of oligourea foldamers as tool to improve the pharma-
ceutical properties of GLP-1, a 31 amino acid peptide hormone involved in metabolism and
glycemic control. Our strategy consists in replacing four consecutive amino acids of GLP-1 by
three consecutive ureido residues by capitalizing on the structural resemblance of oligourea
and α-peptide helices. The efficacy of the approach is demonstrated with three GLP-1-
oligourea hybrids showing prolonged activity in vivo. Our findings should enable the use of
oligoureas in other peptides to improve their pharmaceutical properties and may provide new
therapeutic applications.
https://doi.org/10.1038/s41467-019-08793-y OPEN
1 UREKA—ImmuPharma Group, 2 rue Robert Escarpit, 33607 Pessac, France. 2Univ. Bordeaux, CNRS, CBMN, UMR 5248, Institut Européen de Chimie et Biologie,
2 rue Robert Escarpit, 33607 Pessac, France. Correspondence and requests for materials should be addressed to G.G.(email: g.guichard@iecb.u-bordeaux.fr)
or to S.R.G.(email: sebastien.goudreau@immupharma.com)
NATURE COMMUNICATIONS |          (2019) 10:924 | https://doi.org/10.1038/s41467-019-08793-y |www.nature.com/naturecommunications 1
12
34
56
78
9
0
()
:,;
During the past decade, peptide therapeutics have gainedconsiderable attention in pharmaceutical research anddevelopment (R&D)1–4. Indeed, peptides have proved to
be valuable tools to access extra-cellular targets with medium
to large active sites and they are now intensively investigated to
access intracellular protein–protein interaction (PPI) targets, a
very important topic in recent pharmaceutical research5–10. This
is remarkable considering peptides have important shortcomings
as they generally show poor membrane permeability, poor bioa-
vailability, and short in vivo half-life.
Much efforts have been invested in peptide and peptidomi-
metic chemistries6–11 to address those weaknesses in the hope of
finding an alternative to peptides and recently foldamer research
has attracted much interest12–15. Oligoureas are in the limited list
of such potential foldamers as they offer 3-D space similarity,
metabolic compatibility, water solubility, and flexibility of func-
tionalities16–21. Like peptides, they are easily synthesised by
iterative coupling on solid support and possess their own sec-
ondary, tertiary and quaternary structures based on their
sequences22,23. Most importantly, the oligourea backbone is
resistant to proteases20 and can be interfaced with peptide α-
helices as it adopts an helical conformation that does not disrupt
the peptide α-helix propagation16,21,24. This is noteworthy as (1)
many biologically active peptides contain an α-helix (a large
fraction of PPIs involve an α-helix) and (2) those helix portions
could potentially be replaced or partially replaced by oligoureas
with minimal effect on the binding while improving the proteo-
lytic resistance of the peptide. Such strategy would be a valuable
tool to design peptide therapeutics as their pharmaceutical
properties could be improved. Further investigation was however
needed, as the compatibility of peptide-oligourea hybrids in
biological systems and their utilisation in vivo were
undocumented.
GLP-1 (glucagon-like peptide-1) is an endocrinal peptide
hormone expressed by the pancreas and by many other organs
including the gastrointestinal tract, the heart and the brain25,26. It
is released primarily in response to food intake and controls the
secretion of insulin in function of the glucose level. Its receptor,
GLP-1R is a member of class B GPCRs (G protein-coupled
receptors) which are characterized by a seven transmembrane
domain at their C-termini and a large extra-cellular domain at
their N-termini27–30. GLP-1, binds to GLP-1R mostly in an α-
helix conformation with a large surface of contact with both the
extra-cellular domain and the seven transmembrane domain27,30.
In vivo, GLP-1 has a half-life of only 2–3 min, preventing its
therapeutic utilisation31–35. The identified proteases responsible
for its rapid decay are DPP-4 (dipeptidyl peptidase-4)34, which
cleaves selectively between residues 2 and 3, and NEP 24.1135,
which cleaves at multiple sites. Different strategies were used to
improve the peptide half-life including sequence modifications
(exenatide, lixisenatide)36,37, conjugation to molecules with pro-
pensity to bind albumin (liraglutide, semaglutide)36,37, fusion to
large proteins (albiglutide, dulaglutide, efpeglenatide)36,37, side
chain cross linking38,39, and α → β-residue replacement40–42
(Fig. 1a).
Owing to its α-helical binding conformation, GLP-1 stroke us
as both a good model for testing α-helix mimicry with oligourea
foldamers and a relevant pharmaceutical target. Indeed GLP-1R
agonists proved to be efficient for the treatment of type 2 diabetes
mellitus37 and studies indicate they could be used in other
indications26,43,44 such as obesity45,46, adverse cardiovascular
events25, cognitive disorders44 and non-alcoholic steatohepatitis
(NASH)47.
Herein we report a series of GLP-1-oligourea hybrids with
moderate to excellent affinity to GLP-1R including three hybrids
with prolonged action in mice.
Results and discussion
Peptide-oligourea hybrids design and functional assay. Our
peptide–oligourea hybrids design started with GLP-1-NH2 and
the introduction of a glycine in position 2 of GLP-1 instead of
alanine (GLP-1-G2, 1) as it is known to prevent DPP-4 degra-
dation31–33. We then identified the amount of consecutive amino
acid residues that can be replaced by ureido units. This aspect was
important considering that GLP-1 has key interactions with GLP-
1R at both ends of the peptide27,30. If an oligourea portion placed
in the middle of the peptide induced a torsion or an elongation
that is not exactly the same as the polypeptide it replaces, a drastic
negative impact on the affinity would be expected. We thus
decided to start our investigation by replacing four consecutive
amino acids (X4) with three consecutive ureido residues (Xu3)
based on our model, suggesting that this combination gives the
best overlaps of the terminal atoms (Fig. 1b). It is noteworthy that
the diameter of the triad helix turn is slightly larger than the
peptide α-helix turn and it should be taken into account when
designing hybrids.
Next, we turned our attention to the side chains of the removed
tetrapeptide. Our model suggested that the projection of the side
chains of Xu residues would not be the same as the native X
residues they replaced (Fig. 1c). Indeed, examination of the model
suggested that the side chain of Xu1 did not project in the same
direction as in X1. However, it suggested that a ureido residue
with its side chain shifted to the second backbone methylene (i.e.
α-C)18 would give a similar projection. The second side chain
(Xu2) gave the best fit with the corresponding α-amino acid side
chain (X2) based on this model. On the other hand, the third
amino acid side chain seemed to be the least imitable as it is
superimposed with a urea nitrogen of the third ureido residue
Xu3. However, our model also suggested that this third ureido
residue could mimic the fourth amino acid residue (X4) by
changing the substitution pattern (shift to the second methylene
—α-C). Overall, our model suggested that mimicking the precise
projection of α-amino acid side chains was possible although not
necessary trivial.
Considering the relative difficulty to select the most appro-
priate side chains in ureido units to mimic a given tetrapeptide
segment with high fidelity, we thus decided to start with an Alau
triad (AuAuAu) scan for simplification. The objective was to avoid
any negative impact of the amino urea side chains on the potency
so the observed activity would correlate the loss of affinity
predicted from the Ala scan (Table 1 and Fig. 2)48,49. A lower
activity than predicted would mean a negative impact coming
from the backbone modification. In our first round of syntheses,
the known helical portion of GLP-1 spanning residues 9–31 was
scanned with Alau triads (AuAuAu). We avoided, however, to
synthesise hybrids lacking D9 or F22, considering that these
amino acids are requisite for potency (Table 1). All compounds
were synthesized using standard solid-phase synthesis techniques
and microwave assistance22.
The agonistic activity of these hybrids were obtained by
functional assays using cells expressing the GLP-1R and by
measuring the receptor-mediated cAMP produced. As
expected31,32, GLP-1-G2 (1) was 2.5 times less potent than
GLP-1, with still a 50% effective concentration (EC50) of 0.24 nM.
Interestingly, many hybrids from the Alau triad scan proved to be
potent, demonstrating the good overlaps of the oligourea
backbone with the peptide backbone. The most active hybrids
were selected and native side chains were introduced in the
oligourea triads in new rounds of synthesis with focus on
recovering the most important side chain interactions: D9, Y13,
E15, F22 and I23. Table 1 shows a selection of the most
representative results obtained in this study. Interestingly, in most
cases the reintroduction of the native side chains improved the
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potency of the GLP-1-oligourea hybrids. GG2[YuEuAu]14–17 (9)
even gave a better affinity (0.18 nM) than the native peptide 1
(0.24 nM). It is noteworthy that hybrids GG2[DuαAuAu]9–12
(2, 13 nM) and GG2[FuαIuAu]22–25 (16, 62 nM) which contain
native side chains and shifted substitution pattern still preserve
substantial affinity with GLP-1R, although with over a hundred
fold loss compared to the native peptide. Nevertheless, consider-
ing the importance of the modifications, the mere observation
that oligourea triads can mimic those capital interactions is
remarkable. We also investigated the possibility to introduce
two successive triads by synthesizing compound GG2
[YuEuAuAuAuAu]14–21 (23), which comes from the combination
of 9 (0.18 nM) and 14 (4.1 nM). We were delighted to find that 23
was still active (3.4 nM) with a similar potency to 14, considering
that 25% of the GLP-1 sequence was replaced by oligoureas.
Enzymatic and mouse plasma degradation studies. Having in
hands active hybrids, we then turn our attention to their stability
toward proteolysis. Since homooligoureas are fully resistant to
proteases20, improved proteolytic protection was expected for
hybrids compare to their native peptide 1. As mentioned above,
the two main identified proteases for the degradation of GLP-1
in vivo are DPP-4 and NEP-24.11. As the glycine in position 2 of
our analogues prevents the specific DDP-4 cleavage between
residues 2 and 3, our attention was turned toward the later. NEP
24.11 (neutral endopeptidase 24.11, also known as Neprilysin,
CD10, MME and CALLA) is an unspecific membrane protease
that quickly cleaves GLP-1 at multiple sites35. It was showed that
a GLP-1 analogue with improved half-life in a NEP 24.11
degradation assay had prolonged action in mice, therefore mak-
ing this assay relevant to evaluate the potential efficacy in vivo of
our compounds40. In addition to NEP 24.11, mouse plasma was
also utilized to assess the stability of our compounds.
The half-lives of compounds 1, 2, 5, 9, 11, 14, 16, 22 and 23 in
presence of NEP 24.11 and in presence of mouse plasma were
determined by following the decay of the analogues by LCMS
(Table 2). In the NEP 24.11 degradation assay, the native peptide
1 had a half-life of 3.6 h and unfortunately the hybrids 5, 9 and 16
showed diminished half-lives of 2.9, 3.0 and 1.8 h, respectively.
Although these t1/2 values were not significantly different from
the t1/2 of peptide 1 (3.6 h), statistical significance was obtained at
the 4 h time point for these three hybrids demonstrating their
lower stability (Supplementary Fig. 1). Those results were
intriguing, as we did not expect lower proteolytic protection for
some hybrids. Further investigations showed no indication that
the cleavage sites for the destabilized hybrids were located in or
next to the oligourea triads making it more puzzling. Never-
theless, in two cases (22, 23) the permutation of four amino acids
for an oligourea triad improved significantly the proteolytic
protection of the hybrids (Table 2 and Supplementary Fig. 1). It is
also noteworthy that the analogue 23 where eight amino acids
were replaced by two triads had a significant increase of its
half-life.
In mouse plasma degradation assay, the native peptide 1 had a
half-life of 16 min and hybrids 2, 5 and 9 had similar t1/2 of 17, 23
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Fig. 1 Structural analysis. a Schematic representation of different GLP-1 analogues previously reported and of the present approach based on peptide-
oligourea hybrids. b–c Comparison of α-helical and oligourea backbones. b Overlay (side-views) of a peptide oligourea hybrid (derived from the crystal
structures of helical peptide-oligourea hybrids16) over a peptide. c Overlay (side- and top-views) of an oligourea triad (extracted from (b), green backbone)
over a tetrapeptide in α-helical conformation (grey backbone). d Chemical structures of an oligourea backbone, as well of Xu, Xuα, and X residues used in
this study and their associated cartoon representations
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Table 1 Bioactivity of GLP-1 and cognate peptide–oligourea analogues in cAMP production functional assay
Oligourea inserts (triads and hexads) are shown as green boxes. The highlighted amino acids in the GLP-1 sequence generated the highest decrease of activity in the Ala scan: red= very high decrease,
orange= high decrease. Unless otherwise stated, the data are EC50 values ± SE obtained by non-linear regression on 8 points concentration–response curves performed in duplicates (n= 2). Source data
are provided as a Source Data file
EC50 half maximal effective concentration, cAMP cyclic adenosine monophosphate
aGLP-1R potency (EC50)
bStandard error (SE) on the EC50
cPercentage of potency compare to GLP-1-G2
dMean value of 26 experiments
eStandard error of the mean (SEM) on the EC50
fMean value of four experiments.
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Fig. 2 Concentration–response curves for selected analogues. Concentration–response curves for selected analogues to induce increase in cAMP in βTC6
cells expressing the human GLP-1R. The data are mean ± SEM of a typical experiment performed twice (n= 2). Source data are provided as a Source Data
file. cAMP cyclic adenosine monophosphate
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and 17 min, respectively. Interestingly, hybrids 11, 14, 16, 22 and
23 had significantly longer half-lives. In the case of 22, a half-life
of >60 min was observed, which represents over 3.8-folds
improvement compared to peptide 1. Over the eight hybrids
selected, five had improved stability in mouse plasma with the
insertion of the triad at various positions on the peptide. The
proteolytic stability to NEP 24.11 could predict mostly the results
in mouse plasma. The next step was to investigate if these
improvements in half-lives could be transposed in vivo.
In vivo studies. Although improving the proteolytic protection or
the plasmatic stability of some hybrids represented a significant
milestone, the most important question remained: are those
improvements reflected in vivo? To answer this important
question we conducted three sets of studies.
In the first study, we evaluated the effect of the analogues on
the blood glucose concentration of normal mice (Fig. 3). The fed
mice were treated with the analogues and their blood glucose
concentration was monitored before and after dosing for 6 h. The
native peptide GLP-1-G2 (1) showed a decreased of blood glucose
concentration after 30 min, proving its efficacy in vivo, although
for a short time as a rapid raise to the initial concentration level is
observed after 1 h. Hybrids 5 and 9 showed efficacy but no
improvement, indicated by a similar blood glucose curve to
peptide 1 (Fig. 3a). Hybrids 2, 11 and 16 showed no activity
(Fig. 3b) since no initial drop in blood glucose concentration was
observed and the curves resembled the vehicle one. Most
interestingly, hybrids 14, 22 and 23 showed an improved efficacy
compare to the native peptide 1 (Fig. 3c). Indeed, a decrease of
blood glucose concentration is observed after 30 min and the
effect is preserved for 4 h after dosing.
These results were well predicted by the plasma stability of the
hybrids as all the compounds (2, 5 and 9) with similar plasma
stability to peptide 1 gave comparable results in vivo. The
compounds with lower potencies 2 (2%) and 16 (0.4%) showed
no effect after 30 min and were therefore less effective than
peptide 1 (100%), although 16 had longer half-life in plasma (16
vs 38 min). This indicates that passing a certain threshold, the
potency is just not good enough to produce an observable effect.
In the case of hybrid 11, no effect was observed on the blood
glucose after 30 min of the injection. These results were more
difficult to explain as the mouse plasma half-life of 11 is
prolonged (31 min) and the potency (13%) is comparable to 14
(6%), 22 (19%) and 23 (7%). As expected, the three best
compounds in vivo, 14, 22 and 23, had all (1) improved stability
in NEP 24.11 degradation assays, (2) prolonged half-lives in
mouse plasma and (3) decent potency. This is noteworthy as
these analogues are at least 10-fold less potent then GLP-1-G2 (1),
meaning that even if at least 10 times more compound is required
Table 2 NEP 24.11 and mouse plasma degradation assays
Compound Potency (%)a NEP 24.11 t1/2 (h)b SEM (h)c Mouse plasma t1/2 (min)d SEM (min)e In vivo activityf
1 GLP-1-G2-NH2 (GG2) 100 3.6 0.1 16 1 +
2 GG2[DuαAuAu]9–12 2 4.4 0.4 17 1
5 GG2[AuYuAu]11–14 15 2.9 0.3 23 3 +
9 GG2[YuEuAu]14–17 135 3.0 0.2 17 1 +
11 GG2[EuAuAu]15–18 13 3.9 0.4 31* 3
14 GG2[AuAuAu]18–21 6 4.9 0.8 38*** 2 +++
16 GG2[FuαIuAu]22–25 0.4 1.8 0.1 38*** 5
22 GG2[AuAuAu]28–31 19 4.5 0.5 >60*** na +++
23 GG2[YuEuAuAuAuAu]14–21 7 6.1* 0.9 39*** 5 +++
Statistic by one-way ANOVA with Dunnett’s multiple comparison test: *p < 0.05; ***p < 0.001, comparing peptide 1 to oligomers. Source data are provided as a Source Data file
aPercentage of potency (cAMP production) compared to GLP-1-G2 (see Fig. 2)
bHalf-life of GLP-1 analogue in NEP 24.11 degradation assay: mean value of three replicates (n = 3)
cStandard error of the mean on the NEP 24.11 t1/2
dHalf-life of GLP-1 analogue in mouse plasma degradation assay: mean value of four replicates (n = 4)
eStandard error of the mean on the mouse plasma t1/2
fIndicator of in vivo activity: + active, +++ more active
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Fig. 3 Blood glucose study in mice. a–c Blood glucose concentration in normal mice (C57BL/6J, male, 20–25 g, n= 3) before and after dosing: 5 μg per
mouse (50 nmol kg−1) i.v. Formulation: 20 μg mL−1 in PBS 1×. The dosing was done at T0. Data are mean ± SEM. Statistic by two-way ANOVA and
Bonferroni post-test: *p < 0.05, **p < 0.01, ***p < 0.001, comparing vehicle to oligomers. Source data are provided as a Source Data file
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to get the same activity in vitro, they have a significant longer
acting period. Interestingly, the analogue 23 with six consecutive
ureido residues proved to be efficient despite its 7% potency
compared to GLP-1-G2 (1).
In order to validate our results that the pharmaceutical
properties of peptide 1 can be improved by substituting amino
acids with oligourea triads, we conducted a series of IPGTT
studies on the three best hybrids 14, 22 and 23 with peptide 1 as
control (Fig. 4). In the first study, fasted healthy mice were
submitted to an intraperitoneal glucose tolerance test (IPGTT)
5 min after dosing 1 and 14 in order to validate the activity of the
reference peptide 1. As expected both analogues were active,
although 1 had a slightly higher AUC (Fig. 4a). Indeed, after
60 min of the glucose challenge, and therefore 65 min after
dosing, 1 showed no more significant effect compare to the
vehicle while 14 was still active, as expected from the blood
glucose study (Fig. 3). In a second study, an IPGTT was
performed 30 min after i.v. injections of 1, 14 and the vehicle
(Fig. 4b). An effect was observed at T0 before the glucose
challenge but already after 30 min (60 min after dosing) there was
no significant effect on the blood glucose for peptide 1 in
agreement with previous IPGTT study. So when performing an
IPGTT after 30 min of the dosing, the native peptide 1 was
already inactive while hybrid 14 demonstrated full activity as
predicted again from the blood glucose study. A further IPGTT
study was done with a glucose challenge after 2 h of the dosing to
investigate the prolonged activity of hybrids 14, 22 and 23
(Fig. 4c). The native peptide 1 had an IPGTT curve similar to the
vehicle as expected from previous studies. In contrast, the curve
of hybrids 14, 22 and 23 showed a good control of the blood
glucose concentration during the IPGTT which is reflected in the
AUC. An IPGTT was then performed after 4 h of dosing with
compounds 1, 14 and 22 (Fig. 4d). Almost no rise in the blood
glucose was observed at 30 min post glucose challenge and the
effect continued up to 120 min showing that hybrids 14 and 22
are still active after 6 h of the treatment.
To gain additional insight into the pharmacological con-
sequences of modifying the peptide backbone with oligourea
triads, we conducted a pharmacokinetic study with 1 and 22. In
good agreement with the mouse plasma study and the
pharmacodynamics data, hybrid 22 had a longer half-life
compared to peptide 1 (Fig. 5) presumably because it has a
better proteolytic stability, although other factors might be
involved. The NEP study probably indicates the trend while not
being the actual enzyme that determines the in vivo half-life of
our analogues. All in all, these results clearly show that the
activity of peptide 1 in vivo can be prolonged using the oligoureas
triads strategy by improving its pharmacodynamics and pharma-
cokinetics properties.
With that proof of concept in hand, we then investigated the
possibility of combining the peptide/oligourea hybrid approach
with the protraction strategy, which consists of functionalizing a
peptide with a fatty acid chain to promote its binding to albumin
and prolong its in vivo half-life. Semaglutide is a GLP-1 analogue
with an Aib (2-amino isobutyric acid) in position 2 and a C18
chain linked to K20 through a small PEG spacer which was
accepted by the FDA in 2018 for the treatment of diabetes as a
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Fig. 4 IPGTT studies in mice. a–d Intraperitoneal glucose tolerance test (IPGTT) at different time after dosing in fasted normal mice (C57BL/6J, male,
20–25 g). Dosage: 200 μg kg−1 (50 nmol kg−1) i.v. Formulation: 20 μgmL−1 in PBS 1×. IPGTT: glucose 2 g kg−1 i.p. at T0. a IPGTT after 5 min (n= 4).
b IPGTT after 30min (n= 6). c IPGTT after 2 h (n= 6). d IPGTT after 4 h (n= 3). Area under the curve (AUC) of the corresponding IPGTT curve. Data are
mean ± SEM. Statistic by two-way ANOVA and Bonferroni post-test: *p < 0.05, **p < 0.01, ***p < 0.001, comparing vehicle to oligomers; one-way ANOVA
with Dunnett’s multiple comparison test: ##p < 0.01, ###p < 0.001, comparing vehicle to oligomers. Source data are provided as a Source Data file
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once weekly treatment and is presently in phase 3 clinical trial for
a once daily oral treatment50,51. We synthesized hybrid 24 which
is a semaglutide analogue with an oligourea fragment replacing
the four last amino acids (semaglutide-[AuAuAu]28–31) like in
hybrid 22. In vitro (cAMP production functional assay), hybrid
24 was found to be equally potent to semaglutide (Supplementary
Fig. 5). The pharmacodynamics properties of 24 were next
assessed in a study on db/db mice using FDA approved exenatide,
liraglutide and semaglutide as positive controls. A single dose of
analogues or placebo was injected intraperitoneal and the blood
glucose was followed over time. After 48 h, hybrid 24 and
semaglutide were still active while exenatide and liraglutide
showed no more significant activity. Although hybrid 24 and
semaglutide showed similar activities in vitro and in vivo (Fig. 6),
it is noteworthy that hybrid 24 displays a longer half-life than
semaglutide in mouse plasma (160 vs 11 h, Supplementary Fig. 3)
and pancreatin (3.2 vs 0.63 h, Fig. 6b). Because pancreatin
degradation assays are relevant to predict the stability of peptides
in the gastrointestinal tract52, our data thus suggest that hybrid 24
could be suitable for oral administration and the peptide/
oligourea hybrid approach reported here would be used to
improve pharmacokinetic properties of some peptide-based
drugs.
In summary, a simple approach to modify and modulate the
properties of bioactive peptide helices using small foldamer
inserts was developed. It consists of replacing four consecutive
amino acid residues in the sequence of an α-helical peptide by an
α-helicomimetic oligourea segment of three residues to generate
the analogous peptide–oligourea hybrid. Here, the method was
applied in a systematic fashion to the 31 amino acid peptide GLP-
1 to generate a series of GLP-1-oligourea hybrids among which
potent agonists of GLP-1R were identified. Agonists of GLP-1R
have proved to be potent treatment against type 2 diabetes
mellitus and are promising for other indications such as obesity,
NASH, and Alzheimer’s disease. It is noteworthy that three
hybrids out of the eight tested in mice had significantly prolonged
duration of action. This prolonged effect was correlated with both
NEP 24.11 and mouse plasma degradation studies, suggesting an
increased stabilization towards other peptidases present in the
organism. The strategy was then applied to semaglutide, a FDA
approved GLP-1 analogue, to generate hybrid 24 and we showed
that not only the in vivo activity was preserved, but the stability
toward pancreatin was improved opening the way for improve-
ment in oral administration. Overall, this study shows that
replacing four consecutives amino acid residues with an ureido
triad of similar dimension and geometry in a peptide α-helix is a
good strategy to improve its pharmaceutical properties. We
expect this approach to be useful for the development of peptide
therapeutics and we are currently evaluating its generalization to
other peptide sequences and protein targets of therapeutic
interest.
Methods
Synthesis of GLP-1 analogues. Compounds 1–24 were synthesized using solid-
phase synthesis starting from Sieber amide resin (160 mg, loading 0.62 mmol g−1).
The synthesis were conducted with microwave irradiation using the Liberty BlueTM
microwave peptide synthesizer from CEM S.A.S. N-Fmoc-α amino acid (5 equiv)
were coupled with PyBOP (5 equiv) and DIEA (10 equiv) as coupling reagent using
the standard Liberty BlueTM methods. The N-Fmoc protecting group was removed
with 20% piperidine in DMF (3 mL) also with the standard methods. Each acti-
vated monomer (3 equiv) was coupled twice using DIEA (10 equiv) under
microwave irradiation (70 °C, 50W, 20 min) in DMF (4 mL). The reduction of the
azido group was performed twice in a mixture of 1,4-dioxane/H2O (7:3 v/v) (5 mL)
with a 1 M PMe3 solution in THF (10 equiv) under microwave irradiation (50 °C,
50W, 30 min). See supplementary methods for the remaining steps of the synthesis
of 24. After completion of the synthesis, the resin was transferred into a syringe
with a frit, and washed three times with DMF, three times with CH2Cl2 and three
times with Et2O. Cleavage from the resin was performed using 95% TFA with 2.5%
triisopropylsilane and 2.5% water (3 mL). After 2 h the resin was filtered and
discarded. Diethyl ether was added to precipitate the oligomer and the solid was
triturated and filtrated. Semi preparative purification of all compound was per-
formed by HPLC using a C18 ec column (10 × 250 mm, 5 μm).
In vitro pharmacology (EC50). Evaluation of the agonist activity of compounds
1–23 at the mouse GLP-1 receptor endogenously expressed in βTC6 cells, was
determined by measuring their effects on cAMP production using the HTRF
detection method (performed by Cerep S.A., catalogue 2015, ref. 2181). Incubations
of the cells were carried out in microplates at a density of 1.5 × 104 cells per well in
HBSS buffer (Invitrogen) with 20 mM HEPES (pH 7.4) and 500 μM IBMX. The
cells were incubated for 10 min at room temperature with HBSS (basal control), the
test compound or the reference agonist and then lysed. Fluorescence donor (anti-
cAMP antibody labelled with europium cryptate) and the fluorescence acceptor
(D2-labelled cAMP) were then added to the mixture of lysed cells. After 60 min at
room temperature, a microplate reader (Rubystar, BMG) was used to measure the
fluorescence transfer at λex= 337 nm and λem= 620 and 665 nm. The ratio of
the signal measured at 665 nm on signal measured at 620 nm is used to determine
the cAMP concentration. The results are given as a percent of the control response
to 10 nM GLP-1. The standard reference agonist is GLP-1, which is tested in each
experiment at several concentrations to generate a concentration-response curve
from which its EC50 value and SE is calculated using GraphPad Prism.
Enzymatic degradation (NEP 24.11). Stock solutions of the oligomers were
prepared at a concentration of 400 μM in a solution of 50 mM HEPES buffer,
50 mM NaCl, 0.05% Tween-80, pH 8.0. Stock solution of NEP 24.11 was prepared
at a concentration of 100 μg mL−1 in water. Stability of oligomers to NEP 24.11 was
assessed by conducting protease reaction in a 96-well plates at 20 °C. To each well
was added 2 μL of HEPES buffer, 38 μL of the solution of oligomer to be assayed
(final concentration 304 μM) and 10 μL of the solution of enzyme (final con-
centration 20 μg mL−1) for a total volume of 50 μL. Each compound was also
incubated in the absence of the enzyme (12 μL of HEPES buffer and 38 μL of
oligomer). At the indicated time (1, 2, 4, 6 and 22 h) an aliquot of 10 μL was
removed from each experimental reaction and pipetting into 100 μL of 1% TFA
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solution to quench the reaction (t= 0 min was determined using the reaction
without enzyme). A portion of the quenched reaction solution was analysed by
HPLC. The time course of peptide degradation was determined by integrating the
area of each peak in a series of HPLC traces.
Enzymatic degradation (pancreatin). Stock solutions of the oligomers were
prepared at a concentration of 250 μM in DMSO. Stock solution of pancreatin was
prepared at a concentration of 10 mgmL−1 in water. Two microlitres of pancreatin
stock solution was diluted 1/500 with a solution of TRIS 10 mM pH 7.5 to afford a
final concentration of 0.02 mgmL−1. The oligomer was then diluted 1/24 with a
solution of TRIS 10 mM pH 7.5 to afford a final concentration of 10 μM and
incubated at 37 °C (8.3 μL of the oligomer stock solution was diluted with 190 μL of
TRIS 10 mM pH 7.5 and 1.7 μL of the pancreatin solution). Each compound was
also incubated in the absence of pancreatin (8.3 μL of the oligomer stock solution
was diluted with 190 μL of TRIS 10 mM pH 7.5). At the indicated time (20 min and
60 min), an aliquot of 70 μL was removed from each experimental reaction and
pipetting into 175 μL of acetonitrile at 0 °C to quench the reaction (t= 0 min was
determined using the reaction without pancreatin). The samples were frozen at
–80 °C before analysis. The frozen samples were defrosted, stirred with a vortex
5 min and finally centrifuged 5 min at 16 °C (1500 × g). The supernatant was
analysed by LC-MS. The time course of oligomer degradation was determined by
integrating the area of the peak in the extracted ion chromatogram.
Mouse plasma stability. Stock solutions of the oligomers were prepared at a
concentration of 250 μM in water. The oligomer was then diluted 1/50 with a
solution of plasma/PBS pH 7.4 (1:1) to afford a final concentration of 5 μM and
incubated at 37 °C (4 μL of the stock solution was diluted with 196 μL of plasma/
PBS, pH 7.4, 1:1). Each compound was also incubated in the absence of plasma
(196 μL of H2O/PBS, pH 7.4, 1:1). At the indicated time (20 min and 60 min) an
aliquot of 70 μL was removed from each experimental reaction and pipetting into
175 μL of acetonitrile at 0 °C to quench the reaction (t= 0 min was determined
using the reaction without plasma). The samples were frozen at –80 °C before
analysis. The frozen samples were defrosted, stirred with a vortex 5 min and finally
centrifuged 5 min at 16 °C (1500 × g). The supernatant was analysed by LC-MS.
The time course of oligomer degradation was determined by integrating the area of
the peak in the extracted ion chromatogram.
Animals. For the pharmacodynamics studies performed by Physiogenex S.A.S.,
mice were housed in ventilated and enriched housing cages (310 × 125 × 127 mm³)
throughout the experimental phase. The mice were housed in groups of three
animals during the study, on a normal 12 h light cycle (at 8:00 pm lights off), 22 ±
2 °C and 50 ± 10% relative humidity. A standard chow diet (RM1 (E) 801492, SDS)
and tap water were provided ad libitum. All animal protocols done by Physiogenex
S.A.S. were reviewed and approved by the local (Comité régional d’éthique de
Midi-Pyrénées) and national (Ministère de l’Enseignement Supérieur et de la
Recherche) ethics committees (protocol number 05049–06). For the pharmacoki-
netics studies performed by TechMedILL service (PCBIS platform, CNRS
UMS3286), mice were housed in polycarbonate cages (PCT2L12SHT, Allentown)
enriched with play tunnels throughout the experimental phase. The mice were
housed in groups of nine animals during the study, under controlled environment
(22 ± 1 °C) with a relative humidity (50 ± 10%) and a normal 12 h light cycle (at
8:00 pm lights off). A standard chow diet (A04, SAFE, France) and tap water were
provided ad libitum. All animal protocols done by TechMedILL service were
reviewed and approved by the agriculture ministry regulating animal research in
France (Ethics regional committee for animal experimentation Strasbourg, APAFIS
1341#2015080309399690).
Blood glucose experiment in healthy mice. After the acclimation period (at least
5 days), mice (male C57BL/6J mice (Charles River laboratories) 8 weeks old,
20–25 g) were randomized into 10 groups (n= 3 per group) according to their
body weight. They were acutely treated via i.v. route at 10 am (5 μg per mouse).
Blood glucose was measured before dosing and at 30 min, 1, 2, 4, 6 h after dosing in
fed conditions.
IPGTT experiments in mice. After the acclimation period (at least 5 days), mice
(male C57BL/6J mice (Charles River laboratories) 6 weeks old, 20–25 g) were
randomized into groups according to their body weight. The mice were fasted for
6 h prior being acutely treated via i.v. route (5 μg per mouse i.v. (200 μg kg−1,
50 nmol kg−1)) formulated at 20 μg mL−1 in PBS 1×. The IPGTTs were performed
(glucose 2 g kg−1 i.p.) 5 min, 30 min, 2 h or 4 h after dosing and blood glucose was
measured at different time points after the glucose challenge.
Blood glucose experiment in db/db mice. After the acclimation period (at least
5 days), mice (male db/db mice (Charles River laboratories) 7 weeks old, 40 g) were
fasted for 6 h, then blood was collected to measure levels of glucose and insulin.
Mice were then randomized in five homogenous groups (n= 5 per group)
according to their blood glucose, HOMA-IR and body weight. Then, mice were
refed until the day of treatment (at least 2 weeks). At the treatment day, mice
received a single intraperitoneal injection of test items (200 μg kg−1, 50 nmol kg−1)
formulated at 20 μg mL−1 in PBS 1× or vehicle. Blood was collected from the tail
vein and blood glucose levels was measured before the injection and 4, 8, 10, 24 and
48 h after dosing in fed conditions.
Pharmacokinetics. Fifteen mice (male C57BL/6J mice (Janvier Labs, France) 9 weeks
old, 20–25 g) were treated with GLP-1 analogues via i.v. injections (2mg kg−1) for-
mulated at 1 mgmL−1 in PBS 1×. After different time points, mice were sacrificed
and blood samples were collected. The plasma was separated by centrifugation and
the samples were frozen at−80 °C before analysis. A volume of 400 μL of each sample
of plasma was mixed with 1ml of acetonitrile to precipitate the protein and extract the
compound. The sample were then vortexed and centrifuged (15,000 × g, 5 min, 16 °C)
to sediment the precipitated protein. The supernatant was analysed by LC-MS/MS
using a UHPLC coupled to LC-MS 8030 Shimadzu triple quadrupole.
Statistical analysis. GraphPad Prism 7.0 was used for all analyses. Replicate
measurements were taken from different samples. Statistical analyses (two-way
t-test, two-way ANOVA and Bonferroni post-test and one-way ANOVA with
Dunnett’s multiple comparison test) were applied when indicated. P values lower
than 0.05 were considered significant.
Reporting summary. Further information on experimental design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
Data supporting findings of this manuscript are available from the corresponding authors
upon reasonable request. Additional information on the synthesis of the GLP-1
analogues and their characterizations is available in the Supplementary data
(Supplementary Methods and Supplementary Figs. 7–87). The source data underlying
Figs. 2–7 and Supplementary Figs. 1–6 are provided as a Source Data file.
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